View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
August 24, 2018updated 12 Jul 2022 1:12pm

Novartis reports positive results from SOLAR-1 trial

Novartis has reported positive results from the SOLAR-1 trial after the study met its primary endpoint.

Novartis has reported positive results from the SOLAR-1 trial after the study met its primary endpoint.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The global trial is a Phase III, randomised, double-blind, placebo-controlled study evaluating BYL719 (alpelisib) in combination with fulvestrant against fulvestrant alone for the treatment of post-menopausal women.

It also evaluated the study drug combination for men with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) PIK3CA-mutant advanced or metastatic breast cancer that progressed on or following aromatase inhibitor treatment with or without a CDK4/6 inhibitor.

During the trial, a total of 572 patients were randomised in a 1:1 ratio to receive continuous oral treatment of BYL719 at 300mg or placebo once daily in combination with 500mg of fulvestrant intramuscular injections on days one and 15 on the first cycle and day one of each subsequent 28-day cycle.

The patients were distributed on the basis of tumour tissue evaluation to either a PIK3CA-mutant cohort or a PIK3CA non-mutant cohort.

Stratification in the trial was conducted on the basis of visceral metastases and prior CDK4/6 inhibitor treatment.

“BYL719 is the only alpha-specific PI3K inhibitor and the first one to show potential increased benefit and acceptable tolerability for patients.”

The trial’s primary endpoint includes progression-free survival (PFS) for patients with PIK3CA mutation.

Its secondary endpoints comprise overall survival, overall response rate, clinical benefit rate, health-related quality of life, efficacy in PIK3CA non-mutant cohort, safety and tolerability, among others.

Results from the trial have showed that the adverse events observed with BYL719 in combination with fulvestrant were generally similar to those observed in previous BYL719 and fulvestrant trials.

Novartis Oncology Global Drug Development head Samit Hirawat said: “BYL719 is the only alpha-specific PI3K inhibitor and the first one to show potential increased benefit and acceptable tolerability for patients.

“We are encouraged by the results observed in the SOLAR-1 study and look forward to submitting the data to an upcoming medical congress and starting discussions with health authorities worldwide.”

Novartis also plans to continue evaluating data from the SOLAR-1 trial for secondary endpoints.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena